All Releases
 |
Trius Announces Notice of Allowance of U.S. Patent Application Related to Tedizolid Phosphate Combination With Daptomycin
May 13, 2013
|
10.0 KB |
|
| |
SAN DIEGO, May 13, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious infections, announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) on an application r...
|
|
Trius Therapeutics Reports First Quarter 2013 Financial Results
May 7, 2013
|
16.4 KB |
|
| |
SAN DIEGO, May 7, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious infections, announced today its financial results for the first quarter ended March 31, 2013.
"After successfully completing and reportin...
|
|
Trius Therapeutics Presents Clinical Data on Experimental Antibiotic Tedizolid at ECCMID Meeting
Apr 29, 2013
|
13.9 KB |
|
| |
SAN DIEGO and BERLIN, April 29, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery and development of antibiotics for serious infections, announced a range of clinical data for the experimental antibiotic tedizolid phosphate (TR-701) and a presentation on linezolid (Zyvox®)-res...
|
|
Trius Therapeutics to Present Experimental Antibiotic Study Results at ECCMID Meeting
Apr 23, 2013
|
14.4 KB |
|
| |
SAN DIEGO, April 23, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that the results of a large, late-stage human study, called ESTABLISH 2, and multiple other clinical studies from its experimental antibiotic, tedizolid phosphate (TR-701), will be presented in poster and oral presentations at the European Congress ...
|
|
Trius Appoints Seth Fischer to Its Board of Directors
Apr 3, 2013
|
10.5 KB |
|
| |
SAN DIEGO, April 3, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today the appointment of Seth H. Z. Fischer to its Board of Directors. Mr. Fischer was the former Company Group Chairman Johnson & Johnson, Worldwide Franchise Chairman Cordis Corporation responsible for the Cardiovascular Device Business until his retirem...
|
|
Trius to Present at Future Leaders Conference
Apr 2, 2013
|
7.2 KB |
|
| |
SAN DIEGO, April 2, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that Jeffrey Stein, Ph.D., President and Chief Executive Officer of Trius Therapeutics, will provide a corporate presentation on Friday, April 5th at 9:00 a.m. Eastern Time at the Future Leaders in the Biotech Industry Conference at the Millennium Br...
|
|
Trius Announces Positive Results From ESTABLISH 2 Study of Tedizolid in Severe Skin Infections
Mar 25, 2013
|
57.9 KB |
|
| |
Tedizolid Met All Primary and Secondary Efficacy Outcomes Designated by the FDA and EMANDA Filing Expected Second Half of This Year
SAN DIEGO, March 25, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) today announced top-line results from its ESTABLISH 2 Phase 3 clinical trial of tedizolid phosphate (TR-701) for the treatment of...
|
|
Trius Therapeutics Reports 2012 Fourth Quarter and Full Year 2012 Financial Results
Mar 12, 2013
|
17.7 KB |
|
| |
SAN DIEGO, March 12, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious infections, announced today its financial results for the fourth quarter and year ended December 31, 2012.
"As we approach the announc...
|
|
Trius Announces Publication of Tedizolid ESTABLISH 1 Trial in JAMA
Feb 12, 2013
|
12.1 KB |
|
| |
SAN DIEGO, Feb. 12, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery and development of innovative antibiotics for serious infections, announced today that the results from ESTABLISH 1, a Phase 3 study of tedizolid phosphate (TR-701) versus linezolid (Zyvox®) completed in 201...
|
|
Trius Therapeutics, Inc. Announces Exercise of Underwriters' Option to Purchase Additional Shares for Common Stock Offering
Jan 23, 2013
|
10.7 KB |
|
| |
SAN DIEGO, Jan. 23, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) today announced that the underwriters of its previously announced public offering of common stock that priced on January 17, 2013, have exercised their option to purchase an additional 869,135 shares of common stock. With the sale of the additional shares, Trius wil...
|
|
Trius Therapeutics, Inc. Prices Public Offering of Common Stock
Jan 18, 2013
|
10.3 KB |
|
| |
SAN DIEGO, Jan. 18, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) today announced the pricing of an underwritten public offering of 6,300,000 shares of its common stock at a price to the public of $4.75 per share. The gross proceeds to Trius from this offering are expected to be approximately $29,925,000 million, before deducting ...
|
|
Trius Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
Jan 17, 2013
|
10.3 KB |
|
| |
SAN DIEGO, Jan. 17, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Citigroup and Leerink Swann are acting as joint book-running managers and Baird is acting as a co-lead manager. The offering is subject to market conditi...
|
|
Tedizolid Receives Qualified Infectious Disease Product (QIDP) Designation From FDA
Jan 7, 2013
|
10.7 KB |
|
| |
SAN DIEGO, Jan. 7, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery and development of innovative antibiotics for serious infections, announced today that the U.S. Food and Drug Administration (FDA) has designated the company's Phase 3 antibiotic candidate, tedizolid phosphate, as...
|
|
Trius Therapeutics Completes Enrollment in Second Phase 3 Trial of Tedizolid for Skin and Skin Structure Infections
Dec 10, 2012
|
10.0 KB |
|
| |
SAN DIEGO, Dec. 10, 2012 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery and development of innovative antibiotics for life-threatening infections, announced today that it has reached its enrollment objective of 658 patients in the last of its two Phase 3 clinical trials of tedizolid ...
|
|
Trius Therapeutics Ranked Number 42 Fastest Growing Company in North America on Deloitte's 2012 Technology Fast 500(TM)
Nov 14, 2012
|
10.2 KB |
|
| |
SAN DIEGO, Nov. 14, 2012 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for life-threatening infections, announced today it ranked number 42 on Deloitte's Technology Fast 500, a ranking of the five hundred fastest growing t...
|
|
Trius to Present at November Investor Conferences
Nov 12, 2012
|
7.3 KB |
|
| |
SAN DIEGO, Nov. 12, 2012 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that Jeffrey Stein, Ph.D., President and Chief Executive Officer of Trius Therapeutics, will provide a corporate presentation on Wednesday, November 14th at 10:00 a.m. Mountain Time at the 2012 Credit Suisse Healthcare Conference in Phoenix. On Tuesd...
|
|
Trius Therapeutics to Host Analyst and Investor Update Call
Nov 8, 2012
|
8.1 KB |
|
| |
SAN DIEGO, Nov. 8, 2012 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for life-threatening infections, today announced that it will hold an analyst and investor update call Thursday, November 15, 2012 at 4:15 p.m. Eastern ...
|
|
Trius Therapeutics Reports 2012 Third Quarter Financial Results
Nov 5, 2012
|
17.8 KB |
|
| |
SAN DIEGO, Nov. 5, 2012 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for life-threatening infections, announced today its financial results for the third quarter ended September 30, 2012 and provided an update on recent k...
|
|
Tedizolid Safety Data Presented at IDWeek
Oct 19, 2012
|
12.2 KB |
|
| |
SAN DIEGO, Oct. 19, 2012 (GLOBE NEWSWIRE) -- IDWeek 2012 -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for life-threatening infections, today announced that two studies of its lead drug candidate, tedizolid phosphate, are being presented a...
|
|
Trius Therapeutics to Present Data From Tedizolid Clinical Studies at IDWeek Conference
Oct 16, 2012
|
12.2 KB |
|
| |
SAN DIEGO, Oct. 16, 2012 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that the results of multiple studies from its lead antibiotic drug candidate, tedizolid phosphate, will appear in poster presentations at the inaugural IDWeek conference, a joint meeting of the Infectious Disease Society of America, the Society for H...
|
|
|
